GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Change In Receivables

BioLine Rx (BioLine Rx) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Change In Receivables?

BioLine Rx's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means BioLine Rx's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

BioLine Rx's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.36 Mil. It means BioLine Rx's Accounts Receivable increased by $0.36 Mil from Dec. 2022 to Dec. 2023 .

BioLine Rx's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.36 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BioLine Rx's Days Sales Outstanding for the three months ended in Dec. 2023 was 6.81.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BioLine Rx's liquidation value for the three months ended in Dec. 2023 was $-6.46 Mil.


BioLine Rx Change In Receivables Historical Data

The historical data trend for BioLine Rx's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Change In Receivables Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.36

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioLine Rx Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLine Rx  (NAS:BLRX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BioLine Rx's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.358/4.8*91
=6.81

2. In Ben Graham's calculation of liquidation value, BioLine Rx's accounts receivable are only considered to be worth 75% of book value:

BioLine Rx's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=42.994-50.702+0.75 * 0.358+0.5 * 1.953
=-6.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLine Rx Change In Receivables Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines

From GuruFocus